Literature DB >> 16078142

Liposomal formulations of inflammatory bowel disease drugs: local versus systemic drug delivery in a rat model.

Filippos Kesisoglou1, Simon Yuji Zhou, Susan Niemiec, Jordan Wing Lee, Ellen M Zimmermann, David Fleisher.   

Abstract

PURPOSE: Based on adherence to intestinal mucosa, intralumenally administered liposomal formulations of 5-aminosalicylate (5-ASA) and 6-mercaptopurine (6-MP) were studied for their potential to enhance local drug delivery to intestinal tissue for the treatment of inflammatory bowel disease.
METHODS: 5-ASA was encapsulated in standard phospholipid liposomes while 6-MP required encapsulation in nonphospholipid liposomes to obtain equivalent drug loading. Encapsulation efficiency was measured by size-exclusion chromatography/high-performance liquid chromatogtaphy (HPLC). Liposomal formulations or solution of the drugs were injected into unligated jejunum to compare pharmacokinetics and into ligated loops of rat ileum and colon to evaluate local delivery. Dextran sulfate and acetic acid induced colitis were used as models of lower intestinal inflammation. Plasma, tissue and luminal drug and metabolite levels were measured by liquid scintillation counting or HPLC.
RESULTS: Encapsulation efficiency of 6-MP was dependent on lipid content and composition. While liposomal encapsulation significantly reduced systemic absorption of 5-ASA this was not the case for 6-MP. Liposomal adherence to intestinal tissue resulted in increased tissue levels for 5-ASA; however, 6-MP local tissue levels were not improved compared to solution drug.
CONCLUSIONS: Nonphospholipid liposomes optimize encapsulation of 6-MP. While liposomal formulations show potential for local drug delivery to diseased bowel, drug physicochemical properties, absorption, and metabolic profiles dictate tissue-targeting potential. Liposomes reduce systemic availability from paracellular absorption of hydrophilic 5-ASA, but fail to improve local tissue delivery of 6-MP, a molecule absorbed by passive membrane permeation that undergoes extensive first- pass metabolism.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16078142     DOI: 10.1007/s11095-005-5376-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  32 in total

1.  Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules.

Authors:  Staffan Edsbäcker; Per Larsson; Per Wollmer
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-12       Impact factor: 2.566

2.  Intestinal absorption and metabolism of 6-mercaptopurine in the rat small intestine.

Authors:  W R Ravis; J S Wang; S Feldman
Journal:  Biochem Pharmacol       Date:  1984-02-01       Impact factor: 5.858

Review 3.  Medical therapy of inflammatory bowel disease for the 21st century.

Authors:  M Robinson
Journal:  Eur J Surg Suppl       Date:  1998

4.  Reduced systemic availability of an antiarrhythmic drug, bidisomide, with meal co-administration: relationship with region-dependent intestinal absorption.

Authors:  L H Pao; S Y Zhou; C Cook; T Kararli; C Kirchhoff; J Truelove; A Karim; D Fleisher
Journal:  Pharm Res       Date:  1998-02       Impact factor: 4.200

5.  Improvement of aqueous solubility and rectal absorption of 6-mercaptopurine by addition of sodium benzoate.

Authors:  Y Takeichi; T Kimura
Journal:  Biol Pharm Bull       Date:  1994-10       Impact factor: 2.233

6.  Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes.

Authors:  Tareq Taha Jubeh; Yechezkel Barenholz; Abraham Rubinstein
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

7.  Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

Authors:  O Haagen Nielsen; S Bondesen
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

Review 8.  Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.

Authors:  W J Sandborn; S B Hanauer
Journal:  Aliment Pharmacol Ther       Date:  2003-01       Impact factor: 8.171

Review 9.  Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.

Authors:  Hiroshi Nakase; Kazuichi Okazaki; Yasuhiko Tabata; Tsutomu Chiba
Journal:  J Gastroenterol       Date:  2003-03       Impact factor: 7.527

10.  Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study.

Authors:  M Campieri; S Adamo; D Valpiani; A D'Arienzo; G D'Albasio; M Pitzalis; P Cesari; T Casetti; G N Castiglione; F Rizzello; F Manguso; G Varoli; P Gionchetti
Journal:  Aliment Pharmacol Ther       Date:  2003-06-15       Impact factor: 8.171

View more
  3 in total

1.  Preparation, Characterization and In Vitro Evaluation of Eudragit S100-Coated Bile Salt-Containing Liposomes for Oral Colonic Delivery of Budesonide.

Authors:  Hamid Alghurabi; Tatsuaki Tagami; Koki Ogawa; Tetsuya Ozeki
Journal:  Polymers (Basel)       Date:  2022-06-30       Impact factor: 4.967

Review 2.  Advances in Thiopurine Drug Delivery: The Current State-of-the-Art.

Authors:  Ahmed B Bayoumy; Femke Crouwel; Nripen Chanda; Timothy H J Florin; Hans J C Buiter; Chris J J Mulder; Nanne K H de Boer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-09-06       Impact factor: 2.441

3.  Encapsulation of Liposomes within pH Responsive Microspheres for Oral Colonic Drug Delivery.

Authors:  M J Barea; M J Jenkins; Y S Lee; P Johnson; R H Bridson
Journal:  Int J Biomater       Date:  2012-06-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.